FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896787895> ?p ?o ?g. }

• W2896787895 abstract "<h3>Background</h3> Neoadjuvant immunotherapy utilizing novel combinations has the potential to transform the standard of care for locally/regionally advanced melanoma. We hypothesized that neoadjuvant ipilimumab in combination with high dose IFNα2b (HDI) is safe and associated with durable pathologic complete responses (pCR). <h3>Methods</h3> Patients with locally/regionally advanced melanoma were randomized to ipilimumab 3 or 10 mg/kg × 4 doses bracketing definitive surgery, then every 12 weeks × 4. HDI was given concurrently. We evaluated the safety and efficacy of the combination with ipilimumab 3 or 10 mg/kg. The impact on T-cell fraction and clonality were investigated in tumor and blood. <h3>Results</h3> Thirty patients (age 37–76), 15 each at 3 and 10 mg/kg, 18 male and 12 female were treated. Considering immune related adverse events (irAEs) of interest, more grade 3/4 irAEs were seen with ipilimumab 10 mg/kg versus 3 mg/kg (<i>p</i> = 0.042). Among 28 evaluable patients, 11 relapsed, of whom 5 died. Median follow-up for 17 patients who have not relapsed was 32 months. The radiologic preoperative response rate was 36% (95% CI, 21–54); 4 patients at ipilimumab 3 mg/kg and 6 at 10 mg/kg and 2 (at 10 mg/kg) later relapsed. The pCR was 32% (95% CI, 18–51); 5 patients at ipilimumab 3 mg/kg and 4 at 10 mg/kg and one (at 3 mg/kg) had a late relapse. In patients with pCR, T-cell fraction was significantly higher when measured in primary melanoma tumors (<i>p</i> = 0.033). Higher tumor T-cell clonality in primary tumor and more so following neoadjuvant therapy was significantly associated with improved relapse free survival. <h3>Conclusions</h3> Neoadjuvant ipilimumab-HDI was relatively safe and exhibited promising tumor response rates with an associated measurable impact on T-cell fraction and clonality. Most pCRs were durable supporting the value of pCR as a primary endpoint in neoadjuvant immunotherapy trials. <h3>Trial registration</h3> ClinicalTrials.gov, NCT01608594. Registered 31 May 2012." @default.
• W2896787895 created "2018-10-26" @default.
• W2896787895 creator A5002278734 @default.
• W2896787895 creator A5002316087 @default.
• W2896787895 creator A5007239425 @default.
• W2896787895 creator A5020955148 @default.
• W2896787895 creator A5022244759 @default.
• W2896787895 creator A5038344141 @default.
• W2896787895 creator A5043319996 @default.
• W2896787895 creator A5044474059 @default.
• W2896787895 creator A5050352682 @default.
• W2896787895 creator A5059127209 @default.
• W2896787895 creator A5062453358 @default.
• W2896787895 creator A5084195622 @default.
• W2896787895 creator A5086074491 @default.
• W2896787895 date "2018-10-23" @default.
• W2896787895 modified "2023-10-17" @default.
• W2896787895 title "Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire" @default.
• W2896787895 cites W1488069418 @default.
• W2896787895 cites W1558265941 @default.
• W2896787895 cites W1585375233 @default.
• W2896787895 cites W1828940258 @default.
• W2896787895 cites W1894525365 @default.
• W2896787895 cites W1908752382 @default.
• W2896787895 cites W1955397179 @default.
• W2896787895 cites W1975918912 @default.
• W2896787895 cites W1998518732 @default.
• W2896787895 cites W1998927848 @default.
• W2896787895 cites W2001646586 @default.
• W2896787895 cites W2003913995 @default.
• W2896787895 cites W2005955102 @default.
• W2896787895 cites W2027567030 @default.
• W2896787895 cites W2039123767 @default.
• W2896787895 cites W2040190056 @default.
• W2896787895 cites W2043071551 @default.
• W2896787895 cites W2055901890 @default.
• W2896787895 cites W2059569231 @default.
• W2896787895 cites W2066704699 @default.
• W2896787895 cites W2070825440 @default.
• W2896787895 cites W2073800339 @default.
• W2896787895 cites W2074640340 @default.
• W2896787895 cites W2077701601 @default.
• W2896787895 cites W2078142473 @default.
• W2896787895 cites W2087179076 @default.
• W2896787895 cites W2095826876 @default.
• W2896787895 cites W2097995306 @default.
• W2896787895 cites W2107580116 @default.
• W2896787895 cites W2109506765 @default.
• W2896787895 cites W2112045600 @default.
• W2896787895 cites W2112410464 @default.
• W2896787895 cites W2116871245 @default.
• W2896787895 cites W2118449798 @default.
• W2896787895 cites W2119174775 @default.
• W2896787895 cites W2122352172 @default.
• W2896787895 cites W2131621960 @default.
• W2896787895 cites W2131915049 @default.
• W2896787895 cites W2153158488 @default.
• W2896787895 cites W2155991561 @default.
• W2896787895 cites W2160236174 @default.
• W2896787895 cites W2167866281 @default.
• W2896787895 cites W2330359038 @default.
• W2896787895 cites W2342183967 @default.
• W2896787895 cites W2418246656 @default.
• W2896787895 cites W2470428689 @default.
• W2896787895 cites W2528111205 @default.
• W2896787895 cites W2588068986 @default.
• W2896787895 cites W2603690292 @default.
• W2896787895 cites W2607301376 @default.
• W2896787895 cites W2618451551 @default.
• W2896787895 cites W2752210999 @default.
• W2896787895 cites W2752227448 @default.
• W2896787895 cites W2753432434 @default.
• W2896787895 cites W2783914781 @default.
• W2896787895 cites W2797309423 @default.
• W2896787895 cites W4240190405 @default.
• W2896787895 doi "https://doi.org/10.1186/s40425-018-0428-5" @default.
• W2896787895 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6199801" @default.
• W2896787895 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30352626" @default.
• W2896787895 hasPublicationYear "2018" @default.
• W2896787895 type Work @default.
• W2896787895 sameAs 2896787895 @default.
• W2896787895 citedByCount "42" @default.
• W2896787895 countsByYear W28967878952019 @default.
• W2896787895 countsByYear W28967878952020 @default.
• W2896787895 countsByYear W28967878952021 @default.
• W2896787895 countsByYear W28967878952022 @default.
• W2896787895 countsByYear W28967878952023 @default.
• W2896787895 crossrefType "journal-article" @default.
• W2896787895 hasAuthorship W2896787895A5002278734 @default.
• W2896787895 hasAuthorship W2896787895A5002316087 @default.
• W2896787895 hasAuthorship W2896787895A5007239425 @default.
• W2896787895 hasAuthorship W2896787895A5020955148 @default.
• W2896787895 hasAuthorship W2896787895A5022244759 @default.
• W2896787895 hasAuthorship W2896787895A5038344141 @default.
• W2896787895 hasAuthorship W2896787895A5043319996 @default.
• W2896787895 hasAuthorship W2896787895A5044474059 @default.
• W2896787895 hasAuthorship W2896787895A5050352682 @default.
• W2896787895 hasAuthorship W2896787895A5059127209 @default.
• W2896787895 hasAuthorship W2896787895A5062453358 @default.
• W2896787895 hasAuthorship W2896787895A5084195622 @default.

• next